TAKHZYRO® (lanadelumab) for Hereditary Angioedema Patients to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress
The Pharma Data
JULY 11, 2021
Hereditary angioedema is a lifelong condition and research shows that concerns about another attack can limit the way patients lead their lives,” said Prof. TAKHZYRO is a fully human monoclonal antibody that specifically binds and decreases plasma kallikrein activity. All antibody titres were low. Markus Magerl, M.D.,
Let's personalize your content